SUBSCRIBE
SUBSCRIBE

TG Therapeutics, Inc.

NEWS
Pharm Country
TG Therapeutics Announces Voluntary Withdrawal of the BLA/sNDA for U2 to Treat Patients with CLL and SLL
April 15, 2022
 · 
13 min read
Drug Development
TG Therapeutics Announces Oral Presentation of Data from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis at the American Academy of Neurology Annual Meeting
April 6, 2022
 · 
7 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the American Academy of Neurology Annual Meeting
April 4, 2022
 · 
10 min read
Drug Development
FDA Action Alert: BMS, Marinus, Merck and More
March 13, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics Announces Scheduling of Planned Oncologic Drug Advisory Committee Meeting
March 10, 2022
 · 
14 min read
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the American Academy of Neurology Annual Meeting
March 4, 2022
 · 
9 min read
Pharm Country
TG Therapeutics Announces Extension of U.S. FDA BLA/sNDA PDUFA Date for Ublituximab Plus UKONIQ® (U2) to Treat Patients with CLL and SLLFDA sets updated PDUFA goal date of June 25, 2022
March 3, 2022
 · 
15 min read
Drug Development
Biopharma Takes a Decisive Position on the Russia-Ukraine Conflict
March 1, 2022
 · 
4 min read
 · 
Heather McKenzie
Business
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2021 Financial Results Conference call to be held today, Tuesday, March 1, 2022, at 8:30 AM ET
March 1, 2022
 · 
13 min read
Pharm Country
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 25, 2022
 · 
9 min read
Business
TG Therapeutics to Host Conference Call on Fourth Quarter and Year-End 2021 Financial Results and Business UpdateConference call to be held Tuesday, March 1, 2022 at 8:30 AM ET
February 24, 2022
 · 
1 min read
Drug Development
After a Rocky Week, TG Therapeutics Shares Some Good News
February 15, 2022
 · 
3 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Announces Data Presentations from the ULTIMATE I & II Phase 3 Trials of Ublituximab in Multiple Sclerosis to be Presented at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum
February 15, 2022
 · 
8 min read
Sarah Silbiger/Getty Images
Drug Development
FDA Investigating Possible Death Risk Linked to TG Therapeutics’ Lymphoma Drug
February 7, 2022
 · 
2 min read
 · 
Mark Terry
Drug Development
TG Therapeutics Combo Cancer Therapy Hit with Partial Hold
January 27, 2022
 · 
3 min read
 · 
Mark Terry
Pharm Country
TG Therapeutics to Participate in the B. Riley Securities 2022 Virtual Oncology Investor Conference
January 24, 2022
 · 
1 min read
Load More
AWARDS
  • 2026 - Best Places to Work - Badge (1).png
JOBS